Click Chemistry Based Multicomponent Approach in the Synthesis of Spirochromenocarbazole Tethered 1,2,3-triazoles As Potential Anticancer Agents
Overview
Chemistry
Authors
Affiliations
A series of spirochromenocarbazole tethered 1,2,3-triazoles were synthesized via click chemistry based one-pot, five component reaction between N-propargyl isatins, malononitrile, 4-hydroxycarbazole, aralkyl halides and sodium azide using cellulose supported CuI nanoparticles (Cell-CuI NPs) as the heterogeneous catalyst. Antiproliferative activity of all the synthesized compounds was investigated against panel of cancer cell lines such as MCF-7, MDA-MB-231, HeLa, PANC-1, A-549, and THP-1. Many of the synthesized compounds exhibited good anti-proliferative activity against breast (MCF-7 and MDA-MB-231) and cervical (HeLa) cancer cells with IC values less than 10 μM. In case of MCF-7 cells, among the nine compounds that showed good anti-proliferative activity, compounds 6f and 6j were found to be highly potent (IC = 2.13 μM and 4.80 μM, respectively). In case of MDA-MB-231, three compounds (6k, 6j and 6s) showed antiproliferative activity amongst which 6k was the most potent one (IC = 3.78 μM). On the other hand, in cervical cancer HeLa cells, compounds 6b, 6g, 6s and 6u showed excellent antiproliferative activity (IC = 4.05, 3.54, 3.83, 3.35 μM, respectively). All the compounds were found to be nontoxic to the human umbilical vein endothelial cells (HUVECs). AO and EtBr staining and fluorescence microscopy studies of the active compounds (IC < 5 μM) suggested that these compounds induce cell death by apoptosis.
Bishnoi P, Saroha B, Kumar S, Kumar G, Bhardwaj A, Kumari M Mol Divers. 2025; .
PMID: 39918713 DOI: 10.1007/s11030-025-11110-z.
Potent EGFR/PARP-1 inhibition by spirooxindole-triazole hybrids for targeted liver cancer therapy.
Nafie M, Ali M, Alwehaibi M, Alayyaf A, Al-Muhanna M, Almuqati N RSC Adv. 2025; 15(1):58-74.
PMID: 39763621 PMC: 11701428. DOI: 10.1039/d4ra05966b.
Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights.
Hassan S, Farid A, Panda S, Bekheit M, Dinkins H, Fayad W Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065774 PMC: 11280311. DOI: 10.3390/ph17070922.
Abuelizz H, Awad H, Marzouk M, Nasr F, Alqahtani A, Bakheit A RSC Adv. 2022; 9(33):19065-19074.
PMID: 35516906 PMC: 9064907. DOI: 10.1039/c9ra03151k.
Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.
Deng P, Sun G, Zhao J, Yao K, Yuan M, Peng L Front Pharmacol. 2022; 12:793905.
PMID: 35111061 PMC: 8802806. DOI: 10.3389/fphar.2021.793905.